IDEXX Laboratories, Inc. $IDXX Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,003 shares of the company’s stock after selling 26,561 shares during the quarter. ProShare Advisors LLC owned 0.14% of IDEXX Laboratories worth $69,641,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the third quarter worth approximately $31,000. Armstrong Advisory Group Inc. grew its position in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after buying an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of IDEXX Laboratories in the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $35,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. boosted their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Down 0.7%

IDXX opened at $639.79 on Tuesday. The company has a market capitalization of $51.09 billion, a PE ratio of 48.95, a price-to-earnings-growth ratio of 3.93 and a beta of 1.67. The business has a 50-day moving average of $691.95 and a 200-day moving average of $666.49. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the company earned $2.53 earnings per share. The company’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.